

Declaration of Interests Register

TA Committee A

Publication Date: 24/02/2021

Topic: Appraisal of KTE-X19 for treating relapsed or refractory mantle cell lymphoma [ID1313]

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Prof Andrew Davies	Clinical Expert	Direct financial	Has received payment from Gilead for participation in a novel agent (tirabrutinib and entosplentinib) early phase trial for which he is the Principal Investigator at site. This is unrelated to KTE-X19. He has also received payment from Gilead in July 2019 to judge a Fellowship grant award programme that they funded, this is not related to product under discussion.		October 2020		Interests declared and participated in part 1 of the meeting. Agreed by Chair Dr Jane Adam.
Dr Toby Eyre	Clinical Expert	Direct financial	Has received honorarium from Gilead and research support, plus funding to travel to scientific conferences. He has sat on advisory boards for KITE. He also declared indirect financial interests as he has sat on advisory boards and received honorarium for travel to conferences from		October 2020		Interests declared and participated in part 1 of the meeting. Agreed by Chair Dr Jane Adam.

			comparator and potential competitor companies.				
Stephen Scowcroft	Patient Expert	Indirect professional financial	He is employed by Lymphoma Action who receive financial support from a range of pharmaceutical companies, including Kite, for their work programme.				Interests declared and participated in part 1 of the meeting. Agreed by Chair Dr Jane Adam.